Medical device company Zimmer Biomet (NYSE:ZBH) will be announcing earnings results this Tuesday before market open. Here’s what investors should know.
Zimmer Biomet met analysts’ revenue expectations last quarter, reporting revenues of $2.00 billion, up 9.7% year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ full-year EPS guidance estimates but revenue in line with analysts’ estimates.
Is Zimmer Biomet a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Zimmer Biomet’s revenue to grow 9.9% year on year to $2.22 billion, improving from the 4.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.40 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Zimmer Biomet has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 0.7% on average.
Looking at Zimmer Biomet’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. STERIS delivered year-on-year revenue growth of 9.2%, beating analysts’ expectations by 1.1%, and CONMED reported revenues up 7.9%, topping estimates by 1.7%. STERIS traded down 7.7% following the results while CONMED was also down 3.6%.
Read our full analysis of STERIS’s results here and CONMED’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Zimmer Biomet is down 1.1% during the same time and is heading into earnings with an average analyst price target of $102.74 (compared to the current share price of $89.92).
P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.